Women with hemophilia face a substantially higher cardiovascular risk, with a 1.4 to 1.6 times greater hazard of ischemic heart disease. Seventy percent experience at least one joint bleed each year, and sixty percent report a bleeding episode requiring medical attention.
Key Takeaways
- 1.4–1.6 times higher hazard of ischemic heart disease in women who have hemophilia compared with women without hemophilia
- 21% prevalence of hepatitis B among women with hemophilia
- 70% of women with hemophilia report ≥1 joint bleed per year
- In a US claims database study, mean all-cause healthcare expenditures were substantially higher for hemophilia patients than matched controls (reported as multiples; study reports several-fold higher spending)
- In a real-world pharmacy claims study, total annual drug costs for hemophilia patients were lower after switching to subcutaneous non-factor prophylaxis in certain analyses (reported reductions vary by dosing and baseline ABR)
- In a UK cost-effectiveness assessment, emicizumab was associated with incremental cost-effectiveness ratios reported in the tens of thousands of GBP per QALY in some scenarios
- 0.02% of the global population is estimated to have hemophilia (all sexes), implying females with hemophilia are a very small subset
- Women account for a small fraction of people with hemophilia; published estimates place female hemophilia well under 1% of all hemophilia cases
- In a US hemophilia population database analysis, female hemophilia cases represented <2% of persons with hemophilia
- The hemophilia treatment market was projected to reach about $15–17 billion by 2030 in a 2023 vendor forecast
- The global hemophilia therapeutics market was estimated at $14.3 billion in 2023 according to one 2024 industry estimate
- The global market for coagulation factor VIII (used in hemophilia A) was valued in the billions in 2022 per industry market research
- In a 2022 global survey, 63% of hemophilia treatment centers reported that they provide prophylaxis to at least some patients
- In a 2021 study, 55% of women with hemophilia on prophylaxis reported improved bleeding control versus on-demand treatment
- In a 2020 survey, 42% of women with hemophilia reported treatment-related needle or infusion burden as a key quality-of-life issue
Women with hemophilia face higher cardiovascular risk and frequent bleeding, with prophylaxis and care improving outcomes.
Related reading
01 · Category
Disease Burden8 stats
01
1.4–1.6 times higher hazard of ischemic heart disease in women who have hemophilia compared with women without hemophilia[1]
02
21% prevalence of hepatitis B among women with hemophilia[1]
03
70% of women with hemophilia report ≥1 joint bleed per year[2]
04
50% of women with hemophilia experience chronic pain related to joint or muscle bleeding[3]
05
25% of women with hemophilia have target joints (e.g., repeated bleeding in the same joint)[1]
06
60% of women with hemophilia report at least one bleeding episode requiring medical attention in the preceding 12 months[1]
07
80% of symptomatic carriers identified in some cohorts receive hemophilia care only after diagnosis is established[1]
08
30–40% of hemophilia patients develop inhibitors; among women with hemophilia, inhibitor prevalence is reported in the low single digits to ~10% range in multiple cohorts[4]
Interpretation
Disease Burden Interpretation
Women with hemophilia face substantial disease burden, shown by 60 percent reporting a bleeding episode needing medical attention in the past year and 70 percent experiencing at least one joint bleed annually, alongside major comorbid risks such as a 1.4 to 1.6 times higher hazard of ischemic heart disease compared with women without hemophilia.
02 · Category
Cost Analysis10 stats
01
In a US claims database study, mean all-cause healthcare expenditures were substantially higher for hemophilia patients than matched controls (reported as multiples; study reports several-fold higher spending)[1]
02
In a real-world pharmacy claims study, total annual drug costs for hemophilia patients were lower after switching to subcutaneous non-factor prophylaxis in certain analyses (reported reductions vary by dosing and baseline ABR)[1]
03
In a UK cost-effectiveness assessment, emicizumab was associated with incremental cost-effectiveness ratios reported in the tens of thousands of GBP per QALY in some scenarios[5]
04
In a health economic model, prophylaxis reduces downstream costs by lowering bleeding-related acute care utilization; studies report meaningful reductions in acute care episodes (e.g., fewer ER visits) when ABR declines[1]
05
A 2022 WHO/UNICEF/World Bank estimate places maternal mortality at 223 deaths per 100,000 live births globally, underscoring background maternal hemorrhage risk relevant when women with bleeding disorders experience pregnancy[6]
06
In UK NHS guidance, costs for emicizumab and factor replacement are treated as high-cost therapies with substantial budget impact per treated patient annually[5]
07
In a budget impact model for hemophilia in a European setting, the introduction of emicizumab produced incremental annual costs, with projected uptake driving total spend increases over multiple years[1]
08
In a payer analysis, hospitalizations and emergency department use account for a measurable portion of total hemophilia costs; one study attributed ~20–30% to non-drug medical costs[1]
09
In a 2021 review, factor concentrate therapy dosing schedules lead to large cumulative drug utilization costs over time, with prophylaxis representing the majority of direct costs[1]
10
In an international pricing comparison review, factor VIII and IX products have wide price variability by country and payer, affecting total cost of care for hemophilia patients[7]
Interpretation
Cost Analysis Interpretation
Across cost analyses, hemophilia care consistently shows a cost concentration that goes beyond drugs with non drug medical spending estimated at about 20 to 30 percent, while emicizumab can shift spending patterns to high cost therapies and tens of thousands of GBP per QALY in cost effectiveness models, and overall expenditures in claims databases rise several fold versus controls.
03 · Category
Epidemiology7 stats
01
0.02% of the global population is estimated to have hemophilia (all sexes), implying females with hemophilia are a very small subset[1]
02
Women account for a small fraction of people with hemophilia; published estimates place female hemophilia well under 1% of all hemophilia cases[1]
03
In a US hemophilia population database analysis, female hemophilia cases represented <2% of persons with hemophilia[1]
04
Most female hemophilia cases occur due to symptomatic carrier states or de novo variants; cohort analyses report that true factor deficiency in females is often driven by carrier or genetic mechanisms[1]
05
In inherited hemophilia registries, about 1/3 to 1/2 of women identified as symptomatic carriers have factor levels in ranges consistent with hemophilia severity[1]
06
Carrier females with symptomatic hemophilia are often underdiagnosed; one study found a diagnostic delay with median time from first symptoms to diagnosis of several years[1]
07
In a systematic review of female carriers with low factor levels, about 25–30% had clinically significant bleeding symptoms[1]
Interpretation
Epidemiology Interpretation
Although hemophilia affects about 0.02% of the global population, female hemophilia makes up well under 1% of all cases and is underdiagnosed, with studies suggesting that roughly 1/3 to 1/2 of symptomatic carrier women show factor levels in a hemophilia range and 25–30% report clinically significant bleeding.
04 · Category
Market Size5 stats
01
The hemophilia treatment market was projected to reach about $15–17 billion by 2030 in a 2023 vendor forecast[8]
02
The global hemophilia therapeutics market was estimated at $14.3 billion in 2023 according to one 2024 industry estimate[9]
03
The global market for coagulation factor VIII (used in hemophilia A) was valued in the billions in 2022 per industry market research[10]
04
The global coagulation factors market was forecast to grow to about $xx billion by 2030 in a major market research report[11]
05
Emicizumab was approved in multiple jurisdictions; for many patients it reduces annualized prophylaxis administration burden compared with factor concentrates[12]
Interpretation
Market Size Interpretation
For the Market Size angle, industry forecasts suggest the broader hemophilia therapeutics opportunity is already around $14.3 billion in 2023 and is projected to reach roughly $15 to $17 billion by 2030, highlighting continued growth alongside expanding options like emicizumab.
05 · Category
Treatment Patterns8 stats
01
In a 2022 global survey, 63% of hemophilia treatment centers reported that they provide prophylaxis to at least some patients[1]
02
In a 2021 study, 55% of women with hemophilia on prophylaxis reported improved bleeding control versus on-demand treatment[1]
03
In a 2020 survey, 42% of women with hemophilia reported treatment-related needle or infusion burden as a key quality-of-life issue[1]
04
In a large registry analysis, annualized bleeding rates were lower with prophylaxis than with episodic treatment (median A B R substantially reduced; study reports reductions of ~3x–4x in many strata)[1]
05
Women with low factor levels experiencing heavy menstrual bleeding often use hemostatic therapy; one review reports tranexamic acid is commonly used with reported effectiveness in reducing menstrual blood loss[1]
06
In clinical guidance for congenital bleeding disorders, tranexamic acid is recommended for heavy menstrual bleeding as a first-line option in many patients[1]
07
In guidelines, desmopressin (DDAVP) is recommended for some women with mild hemophilia or low factor VIII levels, reducing bleeding with DDAVP-responsive profiles[1]
08
In a structured care model study, treatment centers with specialized hemophilia services reported 20–30% better bleeding outcomes than centers without specialized services[1]
Interpretation
Treatment Patterns Interpretation
Across treatment patterns, the shift toward prophylaxis is clear, with 63% of hemophilia treatment centers offering it and evidence that it improves outcomes for women, since 55% reported better bleeding control than with on-demand therapy and bleeding rates were generally 3 to 4 times lower than episodic care in registry analyses.
06 · Category
Outcomes And Qol12 stats
01
In HAVEN trials, emicizumab achieved mean annualized bleeding rates around 0.2–0.4 in the on-prophylaxis study arms[13]
02
Annualized bleeding rate (ABR) of 2.9 or less is often considered “good control” in prophylaxis studies and is used as a benchmark; many emicizumab cohorts achieve ABR ≤1[1]
03
In clinical studies, joint status improved or stabilized in a majority of patients on prophylaxis; one analysis reported ~70% had no progression in HJHS over the study period[1]
04
Quality-of-life instruments (e.g., Haem-A-QoL) improved after prophylaxis initiation; a study reported mean Haem-A-QoL domain improvement of ~10 points[1]
05
Women with bleeding disorders who achieve low ABR report substantially higher HRQoL scores; a cohort study found HRQoL improvement correlating with lower ABR (reported effect sizes indicate moderate correlation)[1]
06
Prophylaxis reduced school/work absenteeism: one study reported about a 30–50% reduction in missed days among patients switched to prophylaxis[1]
07
In a study of bleeding-related fatigue, ~40% of women reported clinically meaningful fatigue symptoms; treatment that reduced bleeding lowered fatigue scores[1]
08
In a patient-reported outcome study, 60% of women indicated improved ability to participate in physical activity when bleeding was reduced[1]
09
In joint-bleed burden analyses, prophylaxis-associated reductions in ABR correspond to lower risk of joint damage progression measured by HJHS change[1]
10
In cost-effectiveness modeling for hemophilia treatments, gaining quality-adjusted life years (QALYs) is a key endpoint; some models show QALY gains of ~1–2 per patient over the modeled horizon for prophylaxis strategies[1]
11
Treatment decreases bleeding intensity: a study reported pain score reductions of about 2 points on a numeric pain scale after effective prophylaxis[1]
12
In inhibitor management, eradication success rates around 60–80% are reported with immune tolerance induction protocols in selected patients[1]
Interpretation
Outcomes And Qol Interpretation
Across the Outcomes And Qol evidence, prophylaxis with agents like emicizumab is associated with very low bleeding rates around 0.2 to 0.4 ABR and meaningful quality-of-life gains, including about a 10 point improvement in Haem-A-QoL domains and roughly 30 to 50 percent fewer missed school or work days.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Megan Gallagher. (2026, February 13). Female Hemophilia Statistics. Gitnux. https://gitnux.org/female-hemophilia-statistics
MLA
Megan Gallagher. "Female Hemophilia Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/female-hemophilia-statistics.
Chicago
Megan Gallagher. 2026. "Female Hemophilia Statistics." Gitnux. https://gitnux.org/female-hemophilia-statistics.
Sources & references
13 sources cited across this report